



IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2

Stéphanie Cochaud, Jérôme Giustiniani, Clémence Thomas, Emilie Laprevotte, Christian Garbar, Aude-Marie Savoye, Hervé Curé, Corinne Mascaux, Gilles Alberici, Nathalie Bonnefoy, Jean-François Eliaou, Armand Bensussan, Jeremy Bastid

SUPPLEMENTAL INFORMATION



Supplementary Figure 1: Scoring used in breast tissue array. Cancer cases were scored negative (-), weak (+), moderate (++) and strong (+++) depending of the number of the positive cells within the stroma as illustrated (Magnification x20).



Supplementary Figure 2: Expression of IL17A, IL17RA and IL17RC in human cancer cell lines.

Expression of IL17A, IL17RA and IL17RC were analyzed by quantitative RT-PCR.

| | ID (match) | Diagnosis | pTNM | Stage | Histological grade | ER | PR | Her2 | Last follow up | IL- 17A |
|---------------|---------------|-----------------------------|---------|-------|-----------------------|----|----|------|----------------------|------------|
| Primary tumor | 1 | infiltrating duct carcinoma | T2N0M0 | IIA | II | + | + | - | alive | - |
| | 2 | infiltrating duct carcinoma | T2N0M0 | IIA | II | - | + | - | alive | - |
| | 3 | infiltrating duct carcinoma | T2N2aM0 | IIIA | II | - | + | - | alive | ++ |
| | 4 | infiltrating duct carcinoma | T2N2aM0 | IIIA | III | + | - | + | dead | - |
| | 5 | infiltrating duct carcinoma | T2N0M0 | IIA | III | - | - | - | alive | ++ |
| | 6 | infiltrating duct carcinoma | T2N0M0 | IIA | II | + | - | - | alive | - |
| | 7 | infiltrating duct carcinoma | T3N3aM0 | IIIC | II | + | - | - | dead | - |
| | 8 | infiltrating duct carcinoma | T3N0M0 | IIB | II | - | - | - | alive | +++ |

| | | | | | | | | | | |
|-----|---------|---------------------------------|----------|------|---------|---|---|---|-------|-----|
| | 9 | infiltrating duct carcinoma | T2N2aM0 | IIIA | III | - | - | - | alive | - |
| | 10 | infiltrating duct carcinoma | T2N0M0 | IIA | II | - | - | - | alive | + |
| | 11 | infiltrating duct carcinoma | T2N0M0 | IIA | III | - | - | + | alive | + |
| | 12 | infiltrating duct carcinoma | T2N0M0 | IIA | III | + | + | - | alive | - |
| | 13 | infiltrating duct carcinoma | T2N0M0 | IIA | III | - | - | - | dead | - |
| | 14 | sarcomatoid carcinoma | T2N1aM0 | IIB | III | - | - | + | alive | +++ |
| | 15 | infiltrating duct carcinoma | T3N1aM0 | IIIA | III | + | - | - | alive | +++ |
| | 16 | infiltrating duct carcinoma | T2N1miM0 | IIB | II | + | + | - | alive | - |
| | 17 | infiltrating duct carcinoma | T2N1miM0 | IIB | II | - | + | - | alive | ++ |
| | 18 | intrадuctal papillary carcinoma | T2N0M0 | IIA | unknown | + | + | - | alive | + |
| | 19 | infiltrating duct carcinoma | T3N0M0 | IIB | III | - | - | - | alive | - |
| | 20 | atypical medullary carcinoma | T2N1aM0 | IIB | unknown | - | - | - | alive | - |
| | 21 | infiltrating duct carcinoma | T2N0M0 | IIA | III | + | + | - | alive | - |
| | 22 | infiltrating duct carcinoma | T2N0M0 | IIA | unknown | - | - | - | alive | - |
| | 23 | infiltrating duct carcinoma | T2N3aM0 | IIIC | II | + | + | - | alive | - |
| | 24 | infiltrating duct carcinoma | T2N1miM0 | IIB | II | - | + | + | alive | - |
| | 25 | infiltrating duct carcinoma | T2N1aM0 | IIB | III | - | - | + | alive | - |
| | 26 | infiltrating duct carcinoma | T2N1aM0 | IIB | III | + | + | + | alive | - |
| | 27 | infiltrating duct carcinoma | T2N0M0 | IIA | III | + | - | - | alive | - |
| | 28 | infiltrating duct carcinoma | T3N1aM0 | IIIA | II | + | - | - | alive | - |
| | 29 | infiltrating duct carcinoma | T2N1aM0 | IIB | II | - | - | - | dead | - |
| | 30 | infiltrating duct carcinoma | T3N2aM0 | IIIA | II | - | - | + | dead | - |
| | 31 | infiltrating duct carcinoma | T2N3aM0 | IIIC | III | - | - | - | alive | - |
| | 32 | infiltrating duct carcinoma | T2N1aM0 | IIB | III | - | - | - | alive | ++ |
| | 33 | infiltrating duct carcinoma | T2N3aM0 | IIIC | III | - | - | - | dead | ++ |
| | 34 | infiltrating duct carcinoma | T2N3aM0 | IIIC | III | - | - | + | alive | - |
| | 35 | infiltrating duct carcinoma | T2N3aM0 | IIIC | III | - | - | + | alive | - |
| | 36 | infiltrating duct carcinoma | T2N2aM0 | IIIA | III | - | - | - | alive | + |
| | 37 | infiltrating duct carcinoma | T2N1aM0 | IIB | III | - | - | - | alive | - |
| | 38 | infiltrating duct carcinoma | T2N3aM0 | IIIC | III | - | - | + | alive | + |
| | 39 | infiltrating duct carcinoma | T3N2aM0 | IIIA | II | - | - | + | alive | + |
| | 40 | infiltrating duct carcinoma | T3N3aM0 | IIIC | II | - | - | - | dead | - |
| LNM | 41 (31) | metastatic carcinoma | | | | - | - | - | | - |
| | 42 (32) | metastatic carcinoma | | | | - | - | - | | ++ |
| | 43 (33) | metastatic carcinoma | | | | - | - | + | | - |

| | | | | | | | | | | |
|--------|---------|----------------------|--|--|---|---|---|--|--|---|
| | | | | | - | - | + | | | + |
| | 44 (34) | metastatic carcinoma | | | | | | | | |
| | 45 (35) | metastatic carcinoma | | | - | - | + | | | - |
| | 46 (36) | metastatic carcinoma | | | - | - | - | | | - |
| | 47 (37) | metastatic carcinoma | | | - | - | - | | | - |
| | 48 (38) | metastatic carcinoma | | | - | - | + | | | + |
| | 49 (39) | metastatic carcinoma | | | - | - | + | | | - |
| | 50 (40) | metastatic carcinoma | | | - | - | - | | | - |
| Normal | 51 (5) | normal | | | | | | | | + |
| | 52 (31) | normal | | | | | | | | + |
| | 53 (8) | normal | | | | | | | | + |
| | 54 (10) | normal | | | | | | | | + |
| | 55 (11) | normal | | | | | | | | - |
| | 56 (12) | normal | | | | | | | | + |
| | 57 (13) | normal | | | | | | | | + |
| | 58 (34) | normal | | | | | | | | + |
| | 59 (35) | normal | | | | | | | | + |

Supplementary Table 1: Breast tissue arrays data. LNM = lymph node metastasis. Numbers in brackets indicate samples from the same patient (e.g., sample #45 is the LNM biopsy from cancer case #35, and sample #59 is the normal breast tissue from the same patient)